Hmdb loader
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusPredicted
Creation Date2021-03-31 19:50:37 UTC
Update Date2021-09-14 15:47:07 UTC
HMDB IDHMDB0241813
Secondary Accession NumbersNone
Metabolite Identification
Common Name(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine
Description(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10S,11E)-10-hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279 ). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625 ). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Structure
Data?1621803019
SynonymsNot Available
Chemical FormulaC29H45NO7
Average Molecular Weight519.679
Monoisotopic Molecular Weight519.319602793
IUPAC Name3-({10-hydroxy-12-[5-hydroxy-3-oxo-2-(pent-2-en-1-yl)cyclopentyl]dodeca-4,7,11-trienoyl}oxy)-4-(trimethylazaniumyl)butanoate
Traditional Name3-({10-hydroxy-12-[5-hydroxy-3-oxo-2-(pent-2-en-1-yl)cyclopentyl]dodeca-4,7,11-trienoyl}oxy)-4-(trimethylammonio)butanoate
CAS Registry NumberNot Available
SMILES
CCC=CCC1C(C=CC(O)CC=CCC=CCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C)C(O)CC1=O
InChI Identifier
InChI=1S/C29H45NO7/c1-5-6-11-15-24-25(27(33)20-26(24)32)18-17-22(31)14-12-9-7-8-10-13-16-29(36)37-23(19-28(34)35)21-30(2,3)4/h6,8-12,17-18,22-25,27,31,33H,5,7,13-16,19-21H2,1-4H3
InChI KeyYPKGWXVJAWQRPF-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as acyl carnitines. These are organic compounds containing a fatty acid with the carboxylic acid attached to carnitine through an ester bond.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassFatty acid esters
Direct ParentAcyl carnitines
Alternative Parents
Substituents
  • Acyl-carnitine
  • Dicarboxylic acid or derivatives
  • Cyclopentanol
  • Tetraalkylammonium salt
  • Quaternary ammonium salt
  • Cyclic alcohol
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Carboxylic acid salt
  • Carboxylic acid ester
  • Carboxylic acid
  • Carboxylic acid derivative
  • Organic nitrogen compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Organic oxide
  • Hydrocarbon derivative
  • Organic salt
  • Organic zwitterion
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic homomonocyclic compound
Molecular FrameworkAliphatic homomonocyclic compounds
External DescriptorsNot Available
Ontology
Disposition

Source

Route of exposure

Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Spectral PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP10(-0.83) g/LChemAxon
pKa (Strongest Acidic)4.17ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area123.96 ŲChemAxon
Rotatable Bond Count18ChemAxon
Refractivity170.86 m³·mol⁻¹ChemAxon
Polarizability59.78 ųChemAxon
Number of Rings1ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Spectral Properties

Predicted Kovats Retention Indices

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TMS,#1CCC=CCC1C(=O)CC(O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C3734.2Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TMS,#2CCC=CCC1C(=O)CC(O[Si](C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C3705.0Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TMS,#3CCC=CCC1=C(O[Si](C)(C)C)CC(O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C3678.7Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TMS,#4CCC=CCC1C(O[Si](C)(C)C)=CC(O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C3689.7Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,#1CCC=CCC1C(=O)CC(O[Si](C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C3681.5Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,#2CCC=CCC1=C(O[Si](C)(C)C)CC(O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C3675.3Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,#3CCC=CCC1C(O[Si](C)(C)C)=CC(O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C3653.9Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,#4CCC=CCC1=C(O[Si](C)(C)C)CC(O[Si](C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C3685.7Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,#5CCC=CCC1C(O[Si](C)(C)C)=CC(O[Si](C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C3689.9Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TBDMS,#1CCC=CCC1C(=O)CC(O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C3960.1Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TBDMS,#2CCC=CCC1C(=O)CC(O[Si](C)(C)C(C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C3923.9Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TBDMS,#3CCC=CCC1=C(O[Si](C)(C)C(C)(C)C)CC(O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C3944.6Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TBDMS,#4CCC=CCC1C(O[Si](C)(C)C(C)(C)C)=CC(O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C3925.6Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,#1CCC=CCC1C(=O)CC(O[Si](C)(C)C(C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C4094.7Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,#2CCC=CCC1=C(O[Si](C)(C)C(C)(C)C)CC(O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C4121.5Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,#3CCC=CCC1C(O[Si](C)(C)C(C)(C)C)=CC(O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C4096.2Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,#4CCC=CCC1=C(O[Si](C)(C)C(C)(C)C)CC(O[Si](C)(C)C(C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C4122.4Semi standard non polarhttps://arxiv.org/abs/1905.12712
(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,#5CCC=CCC1C(O[Si](C)(C)C(C)(C)C)=CC(O[Si](C)(C)C(C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C4122.9Semi standard non polarhttps://arxiv.org/abs/1905.12712
Spectra

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine 10V, Positive-QTOFNot Available2021-04-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine 20V, Positive-QTOFNot Available2021-04-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine 40V, Positive-QTOFNot Available2021-04-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine 10V, Positive-QTOFsplash10-00di-0000090000-16ce29dfa43e7da511132021-09-22Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine 20V, Positive-QTOFsplash10-0079-9000050000-05b45cdb2c3142f9fad92021-09-22Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine 40V, Positive-QTOFsplash10-000i-9000000000-e9262cbaff8cb4ad0ba62021-09-22Wishart LabView Spectrum

NMR Spectra

Spectrum TypeDescriptionDeposition DateSourceView
Predicted 1D NMR1H NMR Spectrum (1D, 100 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 100 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 1000 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 1000 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 200 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 200 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 300 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 300 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 400 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 400 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 500 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 500 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 600 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 600 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 700 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 700 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 800 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 800 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 900 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 900 MHz, D2O, predicted)2021-09-25Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen LocationsNot Available
Tissue LocationsNot Available
Pathways
Normal Concentrations
Not Available
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Blazenovic I, Kind T, Sa MR, Ji J, Vaniya A, Wancewicz B, Roberts BS, Torbasinovic H, Lee T, Mehta SS, Showalter MR, Song H, Kwok J, Jahn D, Kim J, Fiehn O: Structure Annotation of All Mass Spectra in Untargeted Metabolomics. Anal Chem. 2019 Feb 5;91(3):2155-2162. doi: 10.1021/acs.analchem.8b04698. Epub 2019 Jan 16. [PubMed:30608141 ]
  2. FRITZ IB: Action of carnitine on long chain fatty acid oxidation by liver. Am J Physiol. 1959 Aug;197:297-304. doi: 10.1152/ajplegacy.1959.197.2.297. [PubMed:13825279 ]
  3. Duranti G, Boenzi S, Rizzo C, Rava L, Di Ciommo V, Carrozzo R, Meschini MC, Johnson DW, Dionisi-Vici C: Urine acylcarnitine analysis by ESI-MS/MS: a new tool for the diagnosis of peroxisomal biogenesis disorders. Clin Chim Acta. 2008 Dec;398(1-2):86-9. doi: 10.1016/j.cca.2008.08.018. Epub 2008 Aug 28. [PubMed:18793625 ]
  4. Yu D, Zhou L, Xuan Q, Wang L, Zhao X, Lu X, Xu G: Strategy for Comprehensive Identification of Acylcarnitines Based on Liquid Chromatography-High-Resolution Mass Spectrometry. Anal Chem. 2018 May 1;90(9):5712-5718. doi: 10.1021/acs.analchem.7b05471. Epub 2018 Apr 20. [PubMed:29651844 ]
  5. Yan X, Markey SP, Marupaka R, Dong Q, Cooper BT, Mirokhin YA, Wallace WE, Stein SE: Mass Spectral Library of Acylcarnitines Derived from Human Urine. Anal Chem. 2020 May 5;92(9):6521-6528. doi: 10.1021/acs.analchem.0c00129. Epub 2020 Apr 23. [PubMed:32271007 ]
  6. Zuniga A, Li L: Ultra-high performance liquid chromatography tandem mass spectrometry for comprehensive analysis of urinary acylcarnitines. Anal Chim Acta. 2011 Mar 9;689(1):77-84. doi: 10.1016/j.aca.2011.01.018. Epub 2011 Jan 18. [PubMed:21338760 ]